Open AccessHigh plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer
Author(s) -
Zoltán Herold,
Magdolna Herold,
György Herczeg,
A. Fodor,
Attila Marcell Szász,
Magdolna Dank,
Anikó Somogyi
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i13.4084
Subject(s) - thrombocytosis , medicine , thrombopoietin , colorectal cancer , gastroenterology , platelet , cancer , oncology , stem cell , haematopoiesis , biology , genetics
Colorectal cancer (CRC) is often associated with elevated platelet count (> 400 × 10 9 /L), known as thrombocytosis. The role of CD40 ligand (CD40L), a member of the tumor necrosis factor family, is controversial in CRC. Circulating CD40L is higher in CRC, but its relationship with disease staging and local and distant metastasis is not clear. Although most of the circulating CD40L is produced by platelets, no previous study investigated its relationship with CRC-related thrombocytosis.